Accéder au contenu
Merck

Low dose alpha-2 antagonist paradoxically enhances rat norepinephrine and clonidine analgesia.

Anesthesia and analgesia (2011-05-06)
Brian Milne, Maaja Sutak, Catherine M Cahill, Khem Jhamandas
RÉSUMÉ

Ultralow-dose opioid antagonists prolong opioid antinociception and block tolerance. In this study we determined whether low doses of the α-2 adrenergic receptor (A2-R) antagonist, atipamezole, similarly influenced A2-R-induced antinociception and tolerance. In rats, intrathecal norepinephrine (NE) or clonidine in combination with atipamezole was tested using tail-flick and paw pressure tests. Acute tolerance to NE was induced by serial injections. Low-dose atipamezole significantly prolonged NE and clonidine-induced antinociception. Coadministration of atipamezole with A2-R agonists also prevented loss of agonist potency in the acute tolerance model. This study demonstrates paradoxical effects of low-dose A2-R antagonists augmenting A2-R agonist-induced analgesia.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Atipamezole, ≥98% (HPLC)